Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

European Journal of Haematology

Volumn 66, Issue 2, 2001, Pages 83-88

  Sezer, Orhan ^a   Jakob, Christian ^a   Eucker, Jan ^a   Niemöller, Kathrin ^a   Gatz, Frauke ^a   Wernecke, Klaus Dieter ^a   Possinger, Kurt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Basic fibroblast growth factor (bFGF); Hepatocyte growth factor (HGF); Interleukin 6 (IL 6); Multiple myeloma; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 6; SCATTER FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; LYMPHOKINES; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PARAPROTEINEMIAS; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035121440     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00348.x     Document Type: Article

References (33)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Angiogenesis
3. Tumor angiogenesis and metastasis: Correlation with invasive breast carcinoma
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Vascular physiology. A family of angiogenic peptides
6. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
7. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
8. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
9. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
10. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
11. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
12. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation
13. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
14. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
15. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
16. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
17. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility
18. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product
19. Concomitant expression of hepatocyte growth factor and the receptor c-Met in human myeloma cell lines
20. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma
21. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
22. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
23. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
24. Proposed guidelines for protocol studies. II. Plasma cell myeloma
25. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
26. Serum concentrations of hepatocyte growth factor in breast cancer patients
27. Bone marrow angiogenesis and progression in multiple myeloma
28. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer
29. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
30. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
31. Blood platelets and serum VEGF in cancer patients
32. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma
33. Antitumor activity of thalidomide in refractory multiple myeloma